Two types of human antibodies that target different parts of the Ebola virus synergize their antiviral effects by inhibiting different steps of infection, according to UTMB’s Philipp Ilinykh and colleagues. These new insights into how the human immune system protects against Ebola infections could lead to the development of effective antibody-based therapies. Labonline, Medicine News Line, Bright Surf, Science Media Exchange, Medical Xpress and Infection Control Today also reported the research findings.